Johnson Investment Counsel Inc. Buys Shares of 21,771 GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Johnson Investment Counsel Inc. bought a new stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 21,771 shares of the company’s stock, valued at approximately $1,769,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Meitav Investment House Ltd. bought a new position in GE HealthCare Technologies during the 2nd quarter valued at about $113,000. Center for Financial Planning Inc. bought a new position in GE HealthCare Technologies during the 2nd quarter valued at about $26,000. Aspire Private Capital LLC purchased a new stake in shares of GE HealthCare Technologies during the 2nd quarter valued at about $26,000. Larson Financial Group LLC purchased a new stake in shares of GE HealthCare Technologies during the 2nd quarter valued at about $27,000. Finally, Sanctuary Wealth Management L.L.C. purchased a new stake in shares of GE HealthCare Technologies during the 2nd quarter valued at about $28,000. Institutional investors own 79.18% of the company’s stock.

GE HealthCare Technologies Trading Up 1.5 %

Shares of GEHC opened at $73.00 on Friday. The company has a debt-to-equity ratio of 1.44, a current ratio of 1.25 and a quick ratio of 0.97. GE HealthCare Technologies Inc. has a 1 year low of $53.00 and a 1 year high of $87.83. The company has a 50 day simple moving average of $67.31 and a two-hundred day simple moving average of $73.31. The firm has a market cap of $33.23 billion and a P/E ratio of 21.73.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings data on Tuesday, October 31st. The company reported $0.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.10. The business had revenue of $4.82 billion during the quarter, compared to analyst estimates of $4.80 billion. GE HealthCare Technologies had a net margin of 8.91% and a return on equity of 24.46%. The company’s revenue was up 5.4% on a year-over-year basis. During the same period last year, the firm posted $0.87 EPS. On average, equities analysts expect that GE HealthCare Technologies Inc. will post 3.81 earnings per share for the current fiscal year.

GE HealthCare Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, November 15th. Stockholders of record on Friday, October 20th were given a dividend of $0.03 per share. The ex-dividend date was Thursday, October 19th. This represents a $0.12 dividend on an annualized basis and a dividend yield of 0.16%. GE HealthCare Technologies’s dividend payout ratio is currently 3.57%.

Wall Street Analyst Weigh In

GEHC has been the subject of several research reports. Citigroup initiated coverage on shares of GE HealthCare Technologies in a research report on Tuesday, September 19th. They set a “buy” rating and a $82.00 price target for the company. Bank of America initiated coverage on shares of GE HealthCare Technologies in a research report on Monday, July 31st. They set a “neutral” rating and a $82.00 price target for the company. Wells Fargo & Company initiated coverage on shares of GE HealthCare Technologies in a research report on Wednesday, August 16th. They set an “overweight” rating and a $90.00 price target for the company. Finally, Argus started coverage on shares of GE HealthCare Technologies in a research report on Friday, August 25th. They set a “buy” rating and a $80.00 price target for the company. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, GE HealthCare Technologies currently has an average rating of “Moderate Buy” and a consensus price target of $88.44.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally.